Study on the efficacy and prognosis of dapagliflozin in patients with heart failure with different left ventricular ejection fractions
Objective:To analyze the efficacy and prognostic impact of dapagliflozin on heart failure patients with different left ventricular ejection fractions.Method:200 heart failure patients with varying left ventricular ejection fractions,admitted between October 2022 to November 2023,were selected and categorized into two groups based on their ejection fractions:>40%and≤40%.Both groups received dapagliflozin alongside conventional treatment.Various parameters,including renal function and BNP levels,were assessed after 3 months,followed by a 6-month follow-up.Results:Significant improvements were observed in renal function,BNP levels,cardiac structural parameters,BMI,6-minute walk distance,resting heart rate,and the incidence of various complications in both groups after dapagliflozin treatment(P<0.05).The post-treatment indicators were similar between the two groups(P>0.05).Conclusion:Dapagliflozin demonstrates effective treatment for heart failure patients across various left ventricular ejection fractions,with its efficacy and prognosis unaffected by the ejection fraction.
国家科技期刊平台
NSTL
万方数据
